Travaux scientifiques

Prof. Dr. Gül Başaran

139 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Therapeutic Advances in Medical Oncology, 2026

    DOI 10.1177/17588359261430583 PMID 41835339 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source : OpenAlex

  3. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source : OpenAlex

  4. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-47351-7 PMID 41933152 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  5. Abstract PS4-10-28: Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC: Real-World Analysis of Predictors of pCR and Survival

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-10-28 Source : OpenAlex

  6. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104785 PMID 41980521 Texte intégral en libre accèsSource : OpenAlex

  7. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.1002 3 citations (OpenAlex) Source : OpenAlex

  8. Abstract PS4-01-09: How does proteomics-based prognostic testing compare to genomic tests and online clinical risk prediction tools in early breast cancer patients?

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-01-09 Source : OpenAlex

  9. 415O First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Patient-reported outcomes (PROs) from TROPION-Breast02

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107438 Texte intégral en libre accèsSource : OpenAlex

  10. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  11. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  12. Abstract P4-11-03: Prediciting high risk hormone receptor (HR) positive Her-2 negative early breast cancer (BC) by artificial intelligence (AI) algorithms

    Clinical Cancer Research, 2025

    DOI 10.1158/1557-3265.sabcs24-p4-11-03 Source : OpenAlex

  13. De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer

    JAMA Surgery, 2025

    DOI 10.1001/jamasurg.2024.5913 PMID 39745737 28 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. ASO Visual Abstract: Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in the NEOSENTITURK-trials MF18-02/18-03

    Annals of Surgical Oncology, 2025

    DOI 10.1245/s10434-024-16746-z PMID 39964563 Source : OpenAlex

  15. 42P Concordance of CanAssist breast with Oncotype Dx and MammaPrint in patients with early stage hormone receptor positive breast cancer

    ESMO Open, 2025

    DOI 10.1016/j.esmoop.2025.104596 Texte intégral en libre accèsSource : OpenAlex

  16. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

    Cancers, 2025

    DOI 10.3390/cancers17091592 PMID 40361516 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. HER2 POZITIF METASTATIK MEME KANSERLI HASTALARDA TRASTUZUMAB DERUXTECAN’IN GERÇEK YAŞAM VERILERI: TÜRK ONKOLOJI GRUBU ÇOK MERKEZLI ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2025

    Source : OpenAlex

  18. Quality of life and psychosocial challenges in metastatic breast cancer: the need for tailored interventions in Turkiye

    Future Science OA, 2025

    DOI 10.1080/20565623.2025.2511462 PMID 41020528 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  19. Real-World Outcomes of Adjuvant Paclitaxel and Trastuzumab Therapy in Lymph Node-Negative, HER2-Positive Early-Stage Breast Cancer: A Multicenter Retrospective Data Analysis

    Cancers, 2025

    DOI 10.3390/cancers17142271 PMID 40723155 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  20. Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC).

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.tps617 Texte intégral en libre accèsSource : OpenAlex

  21. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 citation (Europe PMC) Source : OpenAlex

  22. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

    Cancers, 2024

    DOI 10.3390/cancers16193389 PMID 39410009 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  23. 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.103245 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  24. Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)

    Oncology Letters, 2024

    DOI 10.3892/ol.2024.14278 PMID 38385117 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  25. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study

    Japanese Journal of Clinical Oncology, 2024

    DOI 10.1093/jjco/hyae002 PMID 38271177 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Combined analysis of the MF18‐02/MF18‐03 NEOSENTITURK studies: ypN‐positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided

    Cancer, 2024

    DOI 10.1002/cncr.35610 PMID 39476303 13 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  27. Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03

    Annals of Surgical Oncology, 2024

    DOI 10.1245/s10434-024-16472-6 PMID 39623189 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  28. Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study

    Cancer Research, 2024

    DOI 10.1158/1538-7445.sabcs23-ps01-01 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  29. The Relationship Between Body Composition and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

    Cureus, 2024

    DOI 10.7759/cureus.61145 PMID 38933645 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Cognitive Impairment in Caregivers of Cancer Patients: A Cross-sectional Study

    Acta haematologica oncologica Turcica., 2024

    DOI 10.4274/ahot.galenos.2024.89896 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  31. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.24.00144 PMID 38771995 88 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  32. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.545 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  33. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    Future Oncology, 2023

    DOI 10.2217/fon-2022-1287 PMID 37133230 22 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101440 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  35. Abstract PD15-01: PD15-01 AXILLARY NODAL RECURRENCE IS RARE IN PATIENTS WITH NODE-POSITIVE BREAST CANCER UNDERGOING SLNB FOLLOWING NEOADJUVANT CHEMOTHERAPY : EARLY RESULTS OF THE NEOSENTITURK-TRIAL/MF-18-03

    Cancer Research, 2023

    DOI 10.1158/1538-7445.sabcs22-pd15-01 Texte intégral en libre accèsSource : OpenAlex

  36. Combined Analysis of the MF18-02/03 Neosentiturk Studies: Factors Predicting Recurrence in ycN0/ypN-positive Breast Cancer with Sentinel Lymph Node Biopsy - Or Targeted Axillary Dissection - Alone After Neoadjuvant Chemotherapy

    Bursa Uludag University - AVESIS, 2023

    Source : OpenAlex

  37. Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

    Acibadem Universitesi Saglik Bilimleri Dergisi, 2023

    DOI 10.31067/acusaglik.1247538 Texte intégral en libre accèsSource : OpenAlex

  38. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

    Cancers, 2023

    DOI 10.3390/cancers15061667 PMID 36980554 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  39. Abstract P3-02-06: Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

    Cancer Research, 2023

    DOI 10.1158/1538-7445.sabcs22-p3-02-06 Source : OpenAlex

  40. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

    Acta Oncologica, 2023

    DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  41. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients

    Breast cancer research and treatment, 2023

    DOI 10.1007/s10549-023-07074-z PMID 37615792 2 citations (Europe PMC) Source : Europe PMC

  42. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e12610 2 citations (OpenAlex) Source : OpenAlex

  43. Alpelisib induced interstitial lung disease in a patient with advanced breast cancer

    Journal of Oncology Pharmacy Practice, 2022

    DOI 10.1177/10781552221107532 PMID 35730191 3 citations (Europe PMC) Source : OpenAlex

  44. Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e13049 Source : OpenAlex

  45. Sentinel lymph node biopsy with/without axillary dissection in clinically node-positive breast cancer after neoadjuvant chemotherapy

    Bursa Uludag University - AVESIS, 2022

    Source : OpenAlex

  46. What Has Changed in Patients Aged 65 and over Diagnosed with Breast Cancer during the COVID-19 Pandemic: A Single-Center Experience

    Breast Care, 2022

    DOI 10.1159/000523673 PMID 35528628 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  47. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Bursa Uludag University - AVESIS, 2022

    Source : OpenAlex

  48. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.2017952 PMID 34894960 3 citations (Europe PMC) Source : OpenAlex

  49. Abstract PS8-24: Clinical and pathologic characteristics of Turkish breast cancer (BC) patients screened with BRCA1, BRCA2 or 26 - gene inherited cancer panel testing: Single institution experience

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps8-24 Source : OpenAlex

  50. How Do Breast Cancer Patients Present Following COVID-19 Early Peak in a Breast Cancer Center in Turkey?

    European journal of breast health, 2021

    DOI 10.4274/ejbh.galenos.2021.6161 PMID 34263153 7 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC